Management

As President and Chief Executive Officer, Michael Egholm, PhD, leads Standard BioTools in its mission to unleash its next-generation technologies to help drive innovation in the life science industry. Under his direction, Standard BioTools is expected to grow into a best-in-class solutions partner to biopharmaceutical researchers through the expansion of in-house technologies and future acquisitions.

Michael brings more than 25 years of proven leadership in developing and commercializing innovative technologies that drive success in the discovery and development of biopharmaceuticals. Prior to joining Standard BioTools, he served as the Chief Technology Officer of Danaher Life Sciences as well as the founder and leader of the Danaher Corporation’s venture fund. During that time, he led Danaher’s Pall Corporation biopharmaceuticals business, where he played a central role in redesigning its go-to-market structure, leading to the company’s multibillion-dollar revenue today.

Prior to Danaher, Michael was the Chief Technology Officer at Roche’s 454 Life Sciences Corporation, the first company to successfully commercialize next-generation sequencing. There, he spearheaded several large, high-profile programs, including the Neanderthal Sequencing project and the sequencing of the first individual human genome.

An elected member of the Royal Danish Academy of Sciences and Letters, Michael is the named inventor of 40 U.S. patents. While a research associate at the University of Copenhagen, he was lead inventor of peptide nucleic acids (PNA) technology, a synthetic form of DNA, for which he earned his PhD in organic chemistry. More than 2,300 peer-reviewed papers have been published on the properties and uses of PNA, including 42 authored by Michael. He has published more than 100 research papers, with several in the most prestigious peer-reviewed journals, including Science, Nature and The New England Journal of Medicine.

During his personal time, Michael is an avid runner, yogi and scuba diver, and an instrument-rated private pilot.

Alex Kim is Chief Financial Officer of Standard BioTools and has responsibility for Finance, Accounting, IT, and our Legal and Compliance functions. Alex has a passion for improving healthcare and in building businesses by bringing together teams and capabilities to accelerate the pace of innovative breakthroughs. Previously, Alex was Chief Operating Officer.

Prior to joining Standard BioTools, Alex was President of Milliken’s Healthcare Division, a leading provider of advanced wound care products for human health, animal health and sports medicine. He joined Milliken in 2015 initially as Executive Vice President of Corporate Strategy and Corporate Development. From 2012 to 2015, he was Senior Vice President of Strategy and Business Development at Pall Corporation.  And from 2002 to 2012, he worked at Danaher Corporation (NYSE:DHR) in a variety of roles in general management, M&A and business development. Over his career, Alex has completed over 40 transactions, largely focused on healthcare, medical technology and life sciences. He also brings strong operational execution experience, having been intimately involved in integrations and most recently with full operational leadership of a business. In his early career, Alex worked in a variety of engineering design, product development and marketing/sales support roles. Alex has a BS in Mechanical Engineering from Carnegie Mellon University, an MS In Mechanical Engineering from University of Pittsburgh and an MBA from Stanford University.

Anders Davas is the Senior Vice President, Global Operations. He was previously Senior Vice President, Operational Excellence of Standard BioTools since April 2022.
Previously, Anders was Vice President Global Manufacturing of Mölnlycke Health Care, a world-leading medical product and solution company. His responsibilities covered development and execution of manufacturing strategy, design of fit-for purpose supply chain and manufacturing footprint, and day-to day running of large-scale manufacturing operations.

Before joining Mölnlycke, Anders was the General Manager and Director at Pall Corporation in the UK. At Pall, he was instrumental in implementing best operational practices and business operating frameworks to drive operational excellence. Prior to joining Pall, Anders held senior leadership positions with Eaton Corporation and Teleflex Inc.

Anders has over 20 years of proven leadership in complex manufacturing and supply chain settings. He holds an MBA from the Wharton School, a Masters in Operations Management from University of Cambridge and BSc in Mechanical Engineering from Chalmers University of Technology.

In his spare time, Anders enjoys boating, skiing and traveling the world.

Betsy Jensen leads the Standard BioTools human resources function. She brings over 25 years of experience transforming companies to achieve growth and profitability.

Betsy spent nearly eight years leading human resources and internal communications at several Danaher Corporation subsidiaries including Hach Company, Cepheid, Molecular Devices and SCIEX, then served most recently as Chief Human Resources Officer at Gibraltar Industries. Throughout her career, Betsy has partnered with businesses to accelerate growth, embrace continuous improvement, provide leadership, and develop strategy and analytics to drive change and advance innovation. Betsy holds a BS in Business Administration with a concentration in Human Resources Management from San Jose State University.

In her free time, Betsy enjoys spending time with family as well as new culinary experiences, gardening and movies.

Mike Musgnug joins Standard BioTools as Senior Vice President and Chief Commercial Officer and will be focused on growing revenue and driving market adoption of all Standard BioTools products and services.

Mike has spent over 25 years in life science and diagnostics companies. He is known for developing and executing bold strategies to drive profitable growth.

Mike joins us from GrapheneDx, where he served as CEO since 2022. Prior to GrapheneDx, he served at Discovery Life Sciences, Cepheid and Beckman Coulter Life Sciences, both Danaher Companies, and Alere. Mike has held roles of increasing responsibility, including leading Sales, Marketing, Commercial Operations, Product Management, Operations and Strategy. Additionally, Mike serves on several boards.

Mike has a BS in Biology from Marist University, an MS in Biological Sciences, Biotechnology and Bioprocessing from the University of Massachusetts Lowell and an MBA from Marist University.

During his personal time, Mike enjoys motorsports, yoga and travel.

Sean Mackay is Chief Business Officer at Standard BioTools. He has a multidisciplinary background as an executive, investor and investment banker, driving impact in the life sciences tools and therapeutics industries.

Prior to joining Standard BioTools, Sean was the co-founder and CEO of IsoPlexis, a life science tools company, where he led the company through building a team, product development, commercialization, IPO and its eventual sale in 2023.  He also founded a debt advisory practice Lazard Freres, which focused on partnering with public companies for debt restructuring, capital structuring, investments and financing in the context of acquisitions and divestitures. Sean previously served as an Operating Partner at Casdin Capital and sits on multiple boards in the life science tools and bioprocessing space.

Sean is passionate about engaging the scientific and medical community in the commercialization of precision medicine. He has co-authored 20 peer-reviewed scientific publications, including Cell, Nature Medicine and Science Translational Medicine, and has several issued and pending patents related to proteomics, cell-based assays and immunotherapies.

Sean has a BS in Economics from the Wharton School at the University of Pennsylvania, and an MBA from Yale School of Management.

Stephen Williams, MD, PhD, has been the Chief Medical Officer at SomaLogic since 2009, and is responsible for Clinical R&D, Medical Affairs, and Regulatory and Quality. He oversees clinical application of the SomaScan™ Platform and has also had roles in launching the life sciences commercial business, assay development and bioinformatics.

Steve previously had an 18-year career at Pfizer, with roles in experimental medicine and as the Vice President and Worldwide Head of Clinical Technology. He was also on the National Advisory Council for Biomedical Imaging and Bioengineering at the U.S. National Institutes of Health. He helped launch the Alzheimer’s Disease Neuroimaging Initiative and form the FDA-FNIH-PhRMA biomarker consortium.

Steve has degrees in physiology, medicine and surgery, and received his doctorate in medicine and physiology from Charing Cross and Westminster Medical School (now a part of Imperial College London). He also obtained training in diagnostic imaging at the University of Newcastle Upon Tyne.

In his personal time, Steve likes spending time with his family, walking their three dogs, mountain biking, working out and constantly fixing his 1954 Triumph TR2.